세계의 스마트 필 시장 규모는 2024년-2030년의 예측기간 동안 복합 연간 성장률(CAGR) 11.34%의 대폭적인 성장이 전망되고 있습니다. 다양한 요인이 겹쳐 스마트 알약 수요를 촉진하고 있으며, 그 중에서도 노년 인구 증가와 암이나 당뇨병 등 생활 습관병의 이환율 상승이 큰 영향을 미치고 있습니다. 이러한 인구동태의 변화는 첨단 의료 솔루션에 대한 임박한 요구를 만들어내고 스마트 알약의 채용을 촉진하고 있습니다.
게다가 시장은 연구개발 활동 증가와 스마트 알약의 기술 혁신에 충당되는 자금 증가로부터 혜택을 받을 전망입니다. 마이크로카메라의 통합, 소형화, 첨단 마이크로프로세서의 보급과 같은 기술의 진보는 전반적인 시장 상황을 증대시키는데 매우 중요합니다. 이러한 기술적 강화는 스마트 알약의 진단과 치료 능력을 향상시키고 스마트 알약을 현대 의료에서 중요한 도구로 만듭니다.
낮은 침습 처치에 대한 수요의 급증과 환자 편의의 중요성은 시장 성장을 더욱 가속화하고 있습니다. 이러한 요인의 중첩은 시장을 진전시킬 뿐만 아니라 의료진단과 치료방법에 혁명을 일으키는 스마트필의 변화 가능성을 명시하고 있습니다.
또한 스마트필 시장은 신제품 출시와 승인 유입으로 지속적인 성장이 예상됩니다. 이러한 역동적인 상황은 혁신적인 솔루션을 통해 언메트 메디컬 니즈에 대한 대응에 점점 더 초점을 맞추고 있으며, 이로 인해 시장 확대가 촉진됩니다. 2024년부터 2030년까지의 예측 기간은 스마트 알약 제공의 견고한 에코시스템을 볼 수 있어 의료 산업에서의 이 변혁적인 부문의 전반적인 성장과 발전에 크게 기여할 것으로 예측됩니다.
스마트 알약 시장 역학
세계에서 다양한 소화기계 질환의 급증이 스마트 알약 시장을 크게 끌어올릴 전망입니다. 유럽 연방의 크론과 울서 래티티 콜리티스 협회(EFCCA)의 최근 데이터는 세계에서 1 천만 명의 놀라운 수의 사람들이 염증성 장 질환(IBD)과 투병하고 있음을 보여줍니다. 또한 National Institute for Health and Care Excellence는 과민성 장 증후군(IBS)은 일반적으로 영국에서는 20세-30세에 발병하고 일반 인구의 유병률은 연간 10%-20%로 보고, 상황의 중요성을 강조합니다. 주의해야 할 점은 IBS의 증상이 있어도 진찰을 받는 사람이 많아 진짜 유병률이 더 높을 가능성이 있다고 생각됩니다.
GLOBOCAN(2021)에 따르면 소화기계의 무서운 과제인 대장암은 2020년에 세계에서 193만 1, 590명이 새롭게 앓았습니다. 이러한 세계의 소화기 질환의 급증은 진단과 치료 모두에서 매우 중요한 역할을 하는 스마트 알약에 대한 수요 증가를 보여줍니다.
환자의 낮은 침습 처치에 대한 선호 증가가 스마트 알약 시장을 더욱 밀어 넣고 있습니다. 스마트 알약은 고급 캡슐 내시경 검사, 정확한 약물전달, 원활한 원격 환자 모니터링 등 두드러진 이점을 제공합니다. 이러한 특성은 소화기 질환과 암 치료 패러다임에서 스마트 알약 채택의 확대에 기여합니다.
시장 역학은 업계 진출기업에 의한 연구개발(R&D)에 대한 많은 투자와 제휴 및 인수 등 전략적 노력에 의해 더욱 활성화되고 있습니다. 주목할만한 예로는 2021년 1월 EtectRx와 Pear Therapeutics의 제휴가 있습니다. 이 제휴는 의약품에 내장된 무선 센서와 디지털 치료제를 통합하고 복약 준수 데이터와 혁신적인 치료법을 결합하는 것을 목표로 합니다.
결론적으로, 소화기 질환의 유병률 상승, 환자의 저침습 처치로의 시프트, 업계의 전략적 이니셔티브의 중복에 의해 스마트 필 시장은 2024년-2030년에 강력한 성장이 전망됩니다. 지속적인 기술의 진보와 연구 및 파트너십의 협력 활동은 소화기의 진화하는 상황에 대처하는 스마트 알약의 변화 가능성을 명시하고 있습니다.
이 보고서는 세계의 스마트 알약 시장에 대한 조사 분석을 통해 시장 규모와 예측, 촉진요인과 과제, 기업 및 제품 프로파일 등의 정보를 제공합니다.
Smart Pills Market By Product (Capsules And Software And Accessories), Application (Capsule Endoscopy [Small Bowel Video Capsule Endoscopy And Colon Capsule Endoscopy], Patient Monitoring, And Drug Delivery), Disease (Crohn's Disease, Small Bowel Tumors, Inherited Polyposis Syndromes, GI Bleeding, And Others), End-Users (Hospitals & Clinics, Diagnostic Centers, And Others), and geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of gastrointestinal diseases and the increasing demand of minimally invasive approaches across the globe
The global smart pills market is poised for significant growth, projected to achieve a remarkable Compound Annual Growth Rate (CAGR) of 11.34% during the forecast period from 2024 to 2030. A confluence of factors propels the demand for smart pills, with a notable impact stemming from the rising geriatric population and the escalating incidence of lifestyle-related diseases such as cancer and diabetes. This demographic shift is creating a pressing need for advanced healthcare solutions, thereby fostering the adoption of smart pills.
Moreover, the market is set to benefit from heightened research and development endeavors, coupled with increased funding dedicated to smart pill innovation. Technological strides, including the integration of micro-cameras, miniaturization, and the widespread availability of advanced microprocessors, are pivotal in augmenting the overall market landscape. These technological enhancements enhance the diagnostic and therapeutic capabilities of smart pills, positioning them as vital tools in modern healthcare.
The surge in demand for minimally invasive procedures and a growing emphasis on patient convenience further amplify the market's trajectory. The convergence of these factors not only propels the market forward but also underscores the transformative potential of smart pills in revolutionizing medical diagnostics and treatment methodologies.
Furthermore, the smart pills market is poised for sustained growth due to an influx of new product launches and approvals. The dynamic landscape is characterized by an increasing focus on addressing unmet medical needs through innovative solutions, thereby driving the market's expansion. The forecast period from 2024 to 2030 is expected to witness a robust ecosystem of smart pill offerings, contributing significantly to the overall growth and development of this transformative segment within the healthcare industry.
Smart Pills Market Dynamics:
The burgeoning prevalence of diverse gastrointestinal diseases globally is poised to significantly boost the smart pills market. A compelling illustration is provided by recent data from the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA), revealing that a staggering 10 million individuals worldwide grapple with Inflammatory Bowel Disease (IBD). Furthermore, the National Institute for Health and Care Excellence underscores the gravity of the situation, reporting that Irritable Bowel Syndrome (IBS) typically emerges between ages 20 and 30 in the United Kingdom, with a prevalence of 10% to 20% in the general population annually. Alarmingly, it is believed that many with IBS symptoms forego medical consultation, indicating a potentially higher true prevalence.
Colorectal cancer, a formidable gastrointestinal challenge, saw 1,931,590 new global cases in 2020 according to GLOBOCAN 2021. This collective surge in gastrointestinal ailments globally underscores the escalating demand for smart pills, which play a pivotal role in both diagnosis and treatment.
The growing preference for minimally invasive procedures among patients propels the smart pills market further. Smart pills offer distinctive advantages such as advanced capsule endoscopy, precise drug delivery, and seamless remote patient monitoring. These attributes contribute to the increasing adoption of smart pills in the treatment paradigm for gastrointestinal diseases and cancer.
Market dynamics are further catalyzed by substantial investments in Research and Development (R&D) by industry players, coupled with strategic initiatives like partnerships and acquisitions. A noteworthy example is the collaboration between EtectRx and Pear Therapeutics in January 2021. This partnership aims to integrate wireless sensors embedded in medications with digital therapeutics, combining medication adherence data with innovative therapeutic approaches.
In conclusion, the confluence of rising gastrointestinal disease prevalence, the patient shift towards minimally invasive procedures, and strategic industry initiatives position the smart pills market for robust growth from 2024 to 2030. The continual advancements in technology and concerted efforts in research and partnerships underscore the transformative potential of smart pills in addressing the evolving landscape of gastrointestinal healthcare.
However, risks related to the smart pills, the high costs associated with the device, and others may restrict the growth of the overall smart pills market.
Smart Pills Market Segment Analysis:
Smart pills Market by Product (Capsules and Software and Accessories), Application (Capsule Endoscopy [Small Bowel Video Capsule Endoscopy and Colon Capsule Endoscopy], Patient Monitoring, and Drug Delivery), Disease (Crohn's Disease, Small Bowel Tumors, Inherited Polyposis Syndromes, GI Bleeding, and Others), End-Users (Hospitals & Clinics, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
Within the application segment of the smart pills market, the small bowel video capsule endoscopy category is poised to capture a substantial revenue share in 2023, driven by its inherent advantages and diverse applications. Small bowel video capsule endoscopy is a non-invasive procedure employing a miniature wireless camera to capture images of the digestive tract, particularly the small intestine. This innovative approach involves the patient swallowing a capsule, akin to a large pill, housing a camera.
The miniature camera within the small bowel video capsule endoscopy system, encapsulated in a vitamin-sized pill, travels through the digestive tract, capturing thousands of images transmitted to a recorder worn on a belt around the patient's waist. Not only does this procedure offer a detailed view of the small intestine, but it also eliminates the need for invasive measures, aligning with the growing trend towards minimally invasive healthcare technologies.
Furthermore, ongoing advancements in small bowel video capsule endoscopes, particularly in batteries and onboard memory, contribute to their suitability for prolonged usage, enhancing diagnostic capabilities. The market benefits from the presence of technologically advanced devices designed for optimal visualization of the small intestine. For instance, CapsoCam Plus, a product by CapsoVision, stands out by providing a full 360º panoramic direct lateral view of the small bowel mucosa, thereby improving diagnostic accuracy.
The momentum in this segment is further fueled by a series of product launches, regulatory approvals, and strategic initiatives. A notable instance is Medtronic plc's PillCam Small Bowel 3 system, which received clearance from the United States Food and Drug Administration (FDA) in November 2021 for remote endoscopy procedures. The ingestible camera in this capsule facilitates comprehensive visualization of the small bowel, exemplifying the continuous innovation within the field.
In light of these factors, the small bowel video capsule endoscopy category is anticipated to experience substantial growth, contributing significantly to the overall expansion of the smart pills market throughout the forecast period. The convergence of technological advancements, non-invasiveness, and strategic industry moves positions this category as a key driver in shaping the future landscape of smart medical solutions.
North America is expected to dominate the overall Smart Pills Market:
In the year 2023, North America is anticipated to secure the leading share in the smart pills market, driven by several pivotal factors that underscore the region's prominence. The prevalence of chronic diseases, particularly gastrointestinal ailments and associated cancers, stands out as a key growth driver. This is substantiated by the International Foundation for Gastrointestinal Disorders (IFFGD) 2021 report, revealing that 25 to 45 million individuals in the United States were affected by irritable bowel syndrome during that year.
The region's receptiveness to technologically advanced solutions, aiming to streamline patient care, plays a crucial role. The widespread adoption of such solutions is facilitated by a large and discerning customer base, further complemented by the rapidly growing geriatric population. Regulatory approvals for innovative devices, coupled with heightened awareness regarding disease diagnosis through smart pill technology, further contribute to the region's prosperous outlook.
The International Foundation for Gastrointestinal Disorders (IFFGD) report highlights the escalating burden of Inflammatory Bowel Disease (IBD) in Canada, projecting an increase from 322,600 people affected in 2023 to 470,000 in 2035. This trend underscores the growing demand for smart pills for both diagnosis and treatment in response to the rising prevalence of gastrointestinal diseases.
Notably, the region benefits from the presence of key industry players, fostering a conducive environment for product development activities. Additionally, the United States Food and Drug Administration (FDA) has been instrumental in shaping the market trajectory by granting approvals for innovative technologies. An illustrative example is the FDA's clearance in December 2019 for etectRx's ID-CAP System - a pill embedded with sensors that wirelessly communicates with an external system, revolutionizing remote health monitoring without physical contact.
In light of these factors, the smart pills market in North America is poised for substantial growth during the forecast period from 2024 to 2030. The confluence of increasing disease prevalence, regulatory support, technological advancements, and a robust healthcare ecosystem positions the region as a pivotal player in driving the evolution of smart medical solutions.
Smart Pills Market Key Players:
Some of the key market players operating in the smart pills market include Medtronic, Capso Vision Inc., Olympus America, Hoya (Pentax Medical), etectRx, Check-Cap, INTROMEDIC, HQ, Inc., Koninklijke Philips N.V., Novartis AG, BodyCAP, Medisafe, Otsuka America Pharmaceutical, Inc., JINSHAN Science & Technology, Proteus Digital Health, Inc., AnX Robotics, Medimetrics S.A. de C.V., BioCam, BDD Limited, RF Co., Ltd., and others.
Recent Developmental Activities in the Smart Pills Market:
Key Takeaways from the Smart Pills Market Report Study
Target Audience who can be benefited from this Smart Pills Market Report Study
Frequently Asked Questions for the Smart Pills Market:
Smart pills, also known as digital pills or ingestible sensors, are medical capsules or tablets that contain embedded sensors, cameras, or other monitoring devices. These technological components allow the smart pills to collect and transmit data about physiological conditions, medication adherence, and other relevant information from inside the human body. The primary purpose of smart pills is to enhance medical diagnostics, patient monitoring, and drug delivery. They are designed to provide healthcare professionals with real-time information about a patient's health status and response to medication.
The global smart pills market is poised for significant growth, projected to achieve a remarkable Compound Annual Growth Rate (CAGR) of 11.34% during the forecast period from 2024 to 2030.
The demand for smart pills is primarily being boosted by the increasing prevalence of increasing prevalence of chronic diseases, high demand for minimally invasive procedures, an increase in focus on patient convenience, technological development including miniaturization of integrated circuits, increasing product launches and approvals, and others thereby contributing to the overall growth of the smart pills market during the forecast period from 2024-2030.
Some of the key market players operating in the smart pills market include Medtronic, Capso Vision Inc., Olympus America, Hoya (Pentax Medical), etectRx, Check-Cap, INTROMEDIC, HQ, Inc., Koninklijke Philips N.V., Novartis AG, BodyCAP, Medisafe, Otsuka America Pharmaceutical, Inc., JINSHAN Science & Technology, Proteus Digital Health, Inc., AnX Robotics, Medimetrics S.A. de C.V., BioCam, BDD Limited, RF Co., Ltd., and others.
North America is expected to dominate the overall smart pills market during the forecast period from 2024-2030. Owing to factors such as the rising prevalence of chronic diseases and gastrointestinal diseases and related cancers, wide acceptance of technologically advanced solutions to make patient care hassle-free, a large pool of customers, a rapidly growing geriatric population, regulatory approval for new devices, and high awareness about the diagnosis of the disease using smart pill technology among others, the North America smart pills market is expected to growth in coming years.